Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. (Q33344274)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. |
scientific article |
Statements
1 reference
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. (English)
1 reference
Clara D Bloomfield
1 reference
Michael A Caligiuri
1 reference
Richard A Larson
1 reference
Charles A Schiffer
1 reference
Sherif S Farag
1 reference
Stephen L George
1 reference
Edward J Lee
1 reference
Maria Baer
1 reference
Richard K Dodge
1 reference
Brian Becknell
1 reference
Todd A Fehniger
1 reference
Lewis R Silverman
1 reference
Jeffrey Crawford
1 reference
1 September 2002
1 reference
1 reference
2812-2819
1 reference
Identifiers
1 reference